Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, boosting the price target to $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Whitney Ijem has given his Buy rating due to a combination of factors that suggest a positive outlook for Taysha Gene Therapies. The company’s pivotal REVEAL Part B study for TSHA-102 is progressing as planned, with site activations underway and patient enrollment anticipated to begin in the fourth quarter of 2025. This study, which is a single-arm, open-label trial, aims to assess the percentage of patients who achieve or regain developmental milestones after treatment. The management has set a statistical benchmark of a 33% responder rate, which is promising given the 100% responder rate achieved in Part A of the study.
Additionally, Taysha Gene Therapies is financially well-positioned, having ended the second quarter of 2025 with $312.8 million in cash. The recent $230 million raised in May 2025 further strengthens their financial standing, allowing them to be capitalized through Phase 3 data. This financial stability, combined with the positive clinical trial outlook, supports the increased price target of $14, up from the previous $11, and reinforces the Buy recommendation.
According to TipRanks, Ijem is a 5-star analyst with an average return of 17.7% and a 48.72% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Taysha Gene Therapies, and Vertex Pharmaceuticals.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $8.00 price target.